These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 12627321

  • 1. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [Abstract] [Full Text] [Related]

  • 2. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.
    Parker JC, Irwin N, Lavery KS, Green BD, O'Harte FP, Gault VA, Flatt PR.
    Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085
    [Abstract] [Full Text] [Related]

  • 3. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
    Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP.
    Arch Biochem Biophys; 2004 Aug 15; 428(2):136-43. PubMed ID: 15246869
    [Abstract] [Full Text] [Related]

  • 4. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.
    J Endocrinol; 2006 Oct 15; 191(1):93-100. PubMed ID: 17065392
    [Abstract] [Full Text] [Related]

  • 5. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo.
    Gault VA, O'Harte FP, Harriott P, Flatt PR.
    Metabolism; 2003 Jun 15; 52(6):679-87. PubMed ID: 12800091
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
    Irwin N, McClean PL, Cassidy RS, O'harte FP, Green BD, Gault VA, Harriott P, Flatt PR.
    Diabetes Metab Res Rev; 2007 Oct 15; 23(7):572-9. PubMed ID: 17315241
    [Abstract] [Full Text] [Related]

  • 7. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F, Fehmann HC, Göke R, Göke B.
    Diabetes; 1995 Jan 15; 44(1):16-9. PubMed ID: 7813808
    [Abstract] [Full Text] [Related]

  • 8. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.
    Gault VA, O'Harte FP, Harriott P, Flatt PR.
    Biochem Biophys Res Commun; 2002 Feb 08; 290(5):1420-6. PubMed ID: 11820780
    [Abstract] [Full Text] [Related]

  • 9. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide.
    Gault VA, Flatt PR, Harriott P, Mooney MH, Bailey CJ, O'Harte FP.
    J Endocrinol; 2003 Jan 08; 176(1):133-41. PubMed ID: 12525257
    [Abstract] [Full Text] [Related]

  • 10. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
    Irwin N, Green BD, Parker JC, Gault VA, O'Harte FP, Flatt PR.
    Regul Pept; 2006 Jul 15; 135(1-2):45-53. PubMed ID: 16675042
    [Abstract] [Full Text] [Related]

  • 11. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
    Gault VA, Flatt PR, Bailey CJ, Harriott P, Greer B, Mooney MH, O'harte FP.
    Biochem J; 2002 Nov 01; 367(Pt 3):913-20. PubMed ID: 12150711
    [Abstract] [Full Text] [Related]

  • 12. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR.
    J Clin Invest; 1995 Jan 01; 95(1):417-21. PubMed ID: 7814643
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR.
    Biol Chem; 2004 Feb 01; 385(2):169-77. PubMed ID: 15101559
    [Abstract] [Full Text] [Related]

  • 16. Effect of GIP and GLP-1 antagonists on insulin release in the rat.
    Tseng CC, Zhang XY, Wolfe MM.
    Am J Physiol; 1999 Jun 01; 276(6):E1049-54. PubMed ID: 10362617
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
    Graham GV, Conlon JM, Abdel-Wahab YH, Gault VA, Flatt PR.
    Peptides; 2018 Feb 01; 100():182-189. PubMed ID: 29157578
    [Abstract] [Full Text] [Related]

  • 18. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jun 01; 88(6):2706-13. PubMed ID: 12788877
    [Abstract] [Full Text] [Related]

  • 19. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
    O'Harte FP, Ng MT, Lynch AM, Conlon JM, Flatt PR.
    Mol Cell Endocrinol; 2016 Aug 15; 431():133-44. PubMed ID: 27179756
    [Abstract] [Full Text] [Related]

  • 20. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.
    Diabetes Obes Metab; 2002 Sep 15; 4(5):329-35. PubMed ID: 12190996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.